Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer
https://www.facingourrisk.org/XRAY/PARP-inhibitor-ovarian-cancer-survival
Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1910962?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed
This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)
Questions To Ask Your Health Care Provider
- I have finished my first-line treatment. Should I consider maintenance therapy?
- What are my options for maintenance therapy after chemotherapy?
- What type of side effects should I expect on a PARP inhibitor?
Open Clinical Trials
The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.
- NCT03462342 Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI). This study will look at how well patients with recurrent ovarian cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with a PARP inhibitor.
- NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. The purpose of this study is to assess the safety, tolerability and preliminary efficacy of the targeted therapy CYH33 in combination with olaparib in patients who have DDR gene mutations and/or PIK3CA mutations, have progressed on a prior PARP inhibitor and those with recurrent high grade serous ovarian, fallopian tube or primary peritoneal cancer who are platinum resistant or refractory.
- NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. This studies how well adavosertib with or without olaparib work in patients with ovarian cancer that has come back (recurrent).
- NCT04267939: ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer. This study will look at how well people with advanced ovarian cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to people whose ovarian cancer progressed on a PARP inhibitor.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.